Enhancer regulation/endogenous and synthetic enhancer compounds: A neurochemical concept of the innate and acquired drives

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

This review is to summarize experimental evidence and theoretical consideration in support of the concept that a mesencephalic enhancer regulation is the basis of the limited number of innate drives indispensable for the survival of the individual and the species, while a specifically organized telencephalic enhancer regulation is the basis of the acquired drives to reach an unlimited number of dispensable goals. The study is also an overview of the experimental and clinical data supporting the proposal that, due to the progressive decay of the mesencephalic enhancer regulation with the passing of time, the prophylactic administration of a synthetic enhancer substance [(-)-deprenyl, (-)-BPAP] during postdevelopmental life could significantly slow the age-related decay of behavioral performances, prolong life, and prevent the precipitation or delay the onset of Parkinson's disease and Alzheimer's disease.

Original languageEnglish
Pages (from-to)1275-1297
Number of pages23
JournalNeurochemical Research
Volume28
Issue number8
DOIs
Publication statusPublished - Aug 1 2003

Fingerprint

Selegiline
Telencephalon
Parkinson Disease
Alzheimer Disease
Drive

Keywords

  • (-)-deprenyl (Selegiline)
  • Acquired drives
  • Alzheimer's disease
  • Antiaging drugs
  • Depression
  • Enhancer regulation
  • Enhancer substances
  • Innate drives
  • Parkinson's disease
  • R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane[(-)- BPAP]

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry

Cite this

@article{601ab361cf7b4d91beda1e714e83d25a,
title = "Enhancer regulation/endogenous and synthetic enhancer compounds: A neurochemical concept of the innate and acquired drives",
abstract = "This review is to summarize experimental evidence and theoretical consideration in support of the concept that a mesencephalic enhancer regulation is the basis of the limited number of innate drives indispensable for the survival of the individual and the species, while a specifically organized telencephalic enhancer regulation is the basis of the acquired drives to reach an unlimited number of dispensable goals. The study is also an overview of the experimental and clinical data supporting the proposal that, due to the progressive decay of the mesencephalic enhancer regulation with the passing of time, the prophylactic administration of a synthetic enhancer substance [(-)-deprenyl, (-)-BPAP] during postdevelopmental life could significantly slow the age-related decay of behavioral performances, prolong life, and prevent the precipitation or delay the onset of Parkinson's disease and Alzheimer's disease.",
keywords = "(-)-deprenyl (Selegiline), Acquired drives, Alzheimer's disease, Antiaging drugs, Depression, Enhancer regulation, Enhancer substances, Innate drives, Parkinson's disease, R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane[(-)- BPAP]",
author = "J. Knoll",
year = "2003",
month = "8",
day = "1",
doi = "10.1023/A:1024224311289",
language = "English",
volume = "28",
pages = "1275--1297",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Enhancer regulation/endogenous and synthetic enhancer compounds

T2 - A neurochemical concept of the innate and acquired drives

AU - Knoll, J.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - This review is to summarize experimental evidence and theoretical consideration in support of the concept that a mesencephalic enhancer regulation is the basis of the limited number of innate drives indispensable for the survival of the individual and the species, while a specifically organized telencephalic enhancer regulation is the basis of the acquired drives to reach an unlimited number of dispensable goals. The study is also an overview of the experimental and clinical data supporting the proposal that, due to the progressive decay of the mesencephalic enhancer regulation with the passing of time, the prophylactic administration of a synthetic enhancer substance [(-)-deprenyl, (-)-BPAP] during postdevelopmental life could significantly slow the age-related decay of behavioral performances, prolong life, and prevent the precipitation or delay the onset of Parkinson's disease and Alzheimer's disease.

AB - This review is to summarize experimental evidence and theoretical consideration in support of the concept that a mesencephalic enhancer regulation is the basis of the limited number of innate drives indispensable for the survival of the individual and the species, while a specifically organized telencephalic enhancer regulation is the basis of the acquired drives to reach an unlimited number of dispensable goals. The study is also an overview of the experimental and clinical data supporting the proposal that, due to the progressive decay of the mesencephalic enhancer regulation with the passing of time, the prophylactic administration of a synthetic enhancer substance [(-)-deprenyl, (-)-BPAP] during postdevelopmental life could significantly slow the age-related decay of behavioral performances, prolong life, and prevent the precipitation or delay the onset of Parkinson's disease and Alzheimer's disease.

KW - (-)-deprenyl (Selegiline)

KW - Acquired drives

KW - Alzheimer's disease

KW - Antiaging drugs

KW - Depression

KW - Enhancer regulation

KW - Enhancer substances

KW - Innate drives

KW - Parkinson's disease

KW - R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane[(-)- BPAP]

UR - http://www.scopus.com/inward/record.url?scp=0037709764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037709764&partnerID=8YFLogxK

U2 - 10.1023/A:1024224311289

DO - 10.1023/A:1024224311289

M3 - Article

C2 - 12834268

AN - SCOPUS:0037709764

VL - 28

SP - 1275

EP - 1297

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

IS - 8

ER -